Skip to main content
Erschienen in: Clinical Rheumatology 1/2009

01.01.2009 | Original Article

The Bath metrology index as assessed by a trained and an untrained rater in patients with spondylarthropathy: a study of intra- and inter-rater agreements

verfasst von: O. R. Madsen, L. B. Hansen, A. Rytter, C. Suetta, C. Egsmose

Erschienen in: Clinical Rheumatology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The Bath ankylosing spondylitis metrology index (BASMI; range 0–10) has gained widespread use in daily clinical practice as an objective measure of spinal stiffness not only in patients with ankylosing spondylitis (AS) but also in patients with other spondylarthropathies (SpA ). We examined intra-rater and inter-rater reproducibility of BASMI scoring in 30 Danish patients with SpA (median age 40 years, range 22–56 years) fulfilling the European Spondylarthropathy Study Group criteria, 25 of them satisfying the modified New York Criteria for AS. Measurements were performed twice on two different days (median interval 7 days, range 4–11) by a trained physiotherapist (PT) and by an untrained nurse who had undergone a single 1-h training session with the PT. The median BASMI score obtained by the PT on the two test days was 3.5 (range 1–8) and 3.0 (range 1–8), respectively (NS). Test–retest BASMI scores from the PT were significantly correlated (r s = 0.95, p < 0.0001). The 95% likely range for the difference between a patient’s BASMI scores from two tests was ±1.4 corresponding to a minimal detectable difference of ±2 in the individual patient as the scale consists of intervals of 1. Similar results were achieved by the nurse. BASMI scores obtained by the two raters were significantly inter-correlated (r s = 0.95, p < 0.0001). The mean difference between paired BASMI scores obtained by the nurse and the PT on test day 1 was −0.2 with a minimal detectable difference of ±2. A similar result was found using data from test day 2. In conclusion, a change in BASMI less than 2 may be due solely to expected random measurement error. A single 1-h training session allowed an untrained nurse to obtain BASMI results almost identical to those of an experienced PT.
Literatur
1.
Zurück zum Zitat Zochling J, Braun J (2007) Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 21:699–712PubMedCrossRef Zochling J, Braun J (2007) Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 21:699–712PubMedCrossRef
2.
Zurück zum Zitat Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–442PubMedCrossRef Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–442PubMedCrossRef
3.
Zurück zum Zitat Jenkinson TR, Mallorie PA, Whitelock HC (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. J Rheumatol 21:694–698 Jenkinson TR, Mallorie PA, Whitelock HC (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. J Rheumatol 21:694–698
4.
Zurück zum Zitat Sidiropoulos PI, Hatemi G, Song IH et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 47:355–361CrossRef Sidiropoulos PI, Hatemi G, Song IH et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 47:355–361CrossRef
5.
Zurück zum Zitat Hetland ML (2005) DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 23(5 suppl. 39):S205–S207PubMed Hetland ML (2005) DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 23(5 suppl. 39):S205–S207PubMed
6.
Zurück zum Zitat Altman DG, Bland JM (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310PubMed Altman DG, Bland JM (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310PubMed
7.
Zurück zum Zitat Madsen OR (1996) Trunk extensor and flexor strength measured by the Cybex 6000 dynamometer. Assessment of short-term and long-term reproducibility of several strength variables. Spine 21:2770–2776PubMedCrossRef Madsen OR (1996) Trunk extensor and flexor strength measured by the Cybex 6000 dynamometer. Assessment of short-term and long-term reproducibility of several strength variables. Spine 21:2770–2776PubMedCrossRef
8.
Zurück zum Zitat Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227PubMedCrossRef
9.
Zurück zum Zitat Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
10.
Zurück zum Zitat Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed
11.
Zurück zum Zitat Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to evaluate to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index. J Rheumatol 1:2286–2291 Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to evaluate to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index. J Rheumatol 1:2286–2291
12.
Zurück zum Zitat Bland JM, Altman DG (1996) Statistics notes: measurement error. BMJ 313:714 Bland JM, Altman DG (1996) Statistics notes: measurement error. BMJ 313:714
13.
Zurück zum Zitat Cronstedt H, Waldner A, Stenström CH (1999) The Swedish version of the Bath ankylosing spondylitis functional index. Reliability and validity. Scand J Rheumatol Suppl 111:1–9PubMed Cronstedt H, Waldner A, Stenström CH (1999) The Swedish version of the Bath ankylosing spondylitis functional index. Reliability and validity. Scand J Rheumatol Suppl 111:1–9PubMed
14.
Zurück zum Zitat Waldner A, Cronstedt H, Stenström CH (1999) The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol Suppl 111:10–16PubMedCrossRef Waldner A, Cronstedt H, Stenström CH (1999) The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol Suppl 111:10–16PubMedCrossRef
15.
Zurück zum Zitat Pedersen OB, Hansen GO, Svendsen AJ et al (2007) Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish. Scand J Rheumatol 36:22–27PubMedCrossRef Pedersen OB, Hansen GO, Svendsen AJ et al (2007) Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish. Scand J Rheumatol 36:22–27PubMedCrossRef
16.
Zurück zum Zitat Pile KD, Laurent MR, Salmond CE et al (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30:29–34PubMedCrossRef Pile KD, Laurent MR, Salmond CE et al (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30:29–34PubMedCrossRef
17.
Zurück zum Zitat Haywood KL, Garratt AM, Jordan K et al (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology 43:750–757PubMedCrossRef Haywood KL, Garratt AM, Jordan K et al (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology 43:750–757PubMedCrossRef
18.
Zurück zum Zitat Maksymowych WP, Mallon C, Richardson R et al (2006) Development and validation of the Edmonton ankylosing spondylitis metrology index. Arthritis Rheum 55:575–582PubMedCrossRef Maksymowych WP, Mallon C, Richardson R et al (2006) Development and validation of the Edmonton ankylosing spondylitis metrology index. Arthritis Rheum 55:575–582PubMedCrossRef
19.
Zurück zum Zitat Bland JM, Altman DG (1996) Statistics notes: measurement error and correlation coefficients. BMJ 313:41–42PubMed Bland JM, Altman DG (1996) Statistics notes: measurement error and correlation coefficients. BMJ 313:41–42PubMed
20.
Zurück zum Zitat van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146PubMedCrossRef van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146PubMedCrossRef
21.
Zurück zum Zitat Braun J, Baraliakos X, Listing J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67:340–345PubMedCrossRef Braun J, Baraliakos X, Listing J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67:340–345PubMedCrossRef
22.
Zurück zum Zitat van der Heijde D, Landewé R, Feldtkeller E (2008) Proposal of a linear definition of the Bath ankylosing spondylitis metrology index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 67:489–493PubMedCrossRef van der Heijde D, Landewé R, Feldtkeller E (2008) Proposal of a linear definition of the Bath ankylosing spondylitis metrology index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 67:489–493PubMedCrossRef
Metadaten
Titel
The Bath metrology index as assessed by a trained and an untrained rater in patients with spondylarthropathy: a study of intra- and inter-rater agreements
verfasst von
O. R. Madsen
L. B. Hansen
A. Rytter
C. Suetta
C. Egsmose
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 1/2009
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0978-x

Weitere Artikel der Ausgabe 1/2009

Clinical Rheumatology 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.